Illumina (NASDAQ:ILMN) Issues FY 2026 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 5.050-5.200 for the period, compared to the consensus earnings per share estimate of 5.070. The company issued revenue guidance of $4.5 billion-$4.6 billion, compared to the consensus revenue estimate of $4.4 billion.

Illumina Price Performance

Shares of Illumina stock traded down $0.58 during midday trading on Thursday, reaching $133.61. The company had a trading volume of 2,878,991 shares, compared to its average volume of 2,130,796. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The stock has a fifty day simple moving average of $138.59 and a 200 day simple moving average of $115.87. Illumina has a 1-year low of $68.70 and a 1-year high of $155.53. The company has a market capitalization of $20.42 billion, a price-to-earnings ratio of 29.96, a price-to-earnings-growth ratio of 2.25 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.13. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities research analysts forecast that Illumina will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on ILMN shares. Guggenheim upped their target price on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Robert W. Baird set a $109.00 price objective on shares of Illumina in a report on Friday, October 31st. Barclays lifted their target price on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. UBS Group upped their target price on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Finally, Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Six equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $127.18.

Insider Activity

In other news, insider Scott M. Davies sold 323 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Illumina

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP bought a new position in shares of Illumina in the 3rd quarter valued at about $32,000. Advisory Services Network LLC acquired a new position in Illumina during the third quarter valued at approximately $102,000. Headlands Technologies LLC bought a new position in Illumina in the second quarter valued at approximately $165,000. Glenmede Investment Management LP acquired a new position in shares of Illumina during the 3rd quarter worth approximately $220,000. Finally, Voleon Capital Management LP bought a new stake in shares of Illumina during the 3rd quarter worth approximately $220,000. 89.42% of the stock is owned by institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.